Discover how dynamic BH3 profiling can predict responses in lung cancer patients to ALK inhibitors, enhancing personalized ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication. The use of inhibitors against this oncogene — one of the most effective strategies ...

KRAS gene mutations are seen in about 25% of all lung cancer cases. An ALK mutation is a rearrangement of the ALK gene. This mutation occurs in about 5% of NSCLC cases, most commonly in those with ...

The FDA said that Pfizer's drug can be used in adults and children aged one or over with IMTs that carry a mutation in the ALK gene that cannot be removed surgically and have progressed despite ...

In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication. The use of inhibitors against this oncogene — one of the most effective strategies ...

Single guide RNAs (sgRNAs) designed and built to guide Cas9 to bind and cut desired intronic regions in the EML4 and ALK gene targets, trigger the paracentric genomic rearrangement event upon co ...